Newsroom

Publications

New Scientific Publication

Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet

READ MORE »
Overall News

Business Angels Marne-Ardennes

We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)!  This enables Apmonia Therapeutics to

READ MORE »
Press Release

Apmonia Tx Press release

Check out Apmonia Therapeutics’ press release on the company’s corporate organization and i-Lab innovation award.#deeptech #biotech #cancer #reims

READ MORE »
Overall News

i-Lab 2020 Award

We feel very honored to be recipient of the i-Lab 2020 award. Support given to our ambitious project by Ministère de l’Enseignement Supérieur et de

READ MORE »
Overall News

Cancer Biology and Basic Sciences

We are thrilled to announce that Institut national du cancer (INCa) will provide financial support to a unique industry-academic R&D partnership gathering together Apmonia Therapeutics,

READ MORE »
Overall News

Welcome to Reims 2019

Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We

READ MORE »